Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial

Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    The record describes a completed Phase 2 study of intranodal immunotherapy combined with pembrolizumab for follicular lymphoma, including its treatment plan, eligibility criteria, and outcome measures. It also provides study contacts, investigators, record dates, and information about sharing participant data.
    Difference
    57%
    Check dated 2026-11-09T13:54:35.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.8.0 instead of v3.7.2; the page still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T15:49:58.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A banner announces that NIH websites are transitioning from the term “artificial intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T16:39:03.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T21:45:02.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The site footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T04:24:27.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now presents a 403 Forbidden error with a simple header and a Home option. This indicates the study record is inaccessible and the detailed content is no longer displayed.
    Difference
    20%
    Check dated 2026-09-21T22:47:17.000Z thumbnail image

Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.